Ponce F, Marchal T, Magnol JP, et al. A morphological study of 608 cases of canine malignant lymphoma in France with a focus on comparative similarities between canine and human lymphoma morphology. Vet Pathol. 2010;47(3):414-433.
Kaiser HE. Animal neoplasms: A systemic review. In: Kaiser HE, ed. Neoplasms: Comparative Pathology in Animals, Plants and Man. Baltimore, MD: Williams & Wilkins; 1981.
Molten JE, Harvey JW. Tumors of lymphoid and hematopoietic tissue. In: Moulton JE, ed. Tumors in Domestic Animals. 3rd ed. Berkeley, CA: University of California Press; 1990.
Dorn CR, Taylor DO, Schneider R. The epidemiology of canine leukemia and lymphoma. Bibl Haemtol. 1970;36:403-415.
Withrow and McEwen’s Small Animal Clinical Oncology. 4th ed. In: Withrow SJ, Vail DM, eds. Philadelphia, PA: Saunders-Elsevier; 2007.
Thomas R, Smith KC, Ostrander EA, Galibert F, Breen M. Chromosome aberrations in canine multicentric lymphomas detected with comparative genomic hybridisation and a panel of single locus probes. Br J Cancer. 2003;89(8):1530-1537.
Veldhoen N, Stewart J, Brown R, Milner J. Mutations of the p53 gene in canine lymphoma and evidence for germ line p53 mutations in the dog. Oncogene. 1998;16(2):249-255.
Nasir L, Argyle DJ. Mutational analysis of the tumor suppressor gene p53 in lymphosarcoma in two bull mastiffs. Vet Rec. 1999;145(1):23-24.
Modiano JF, Breen M, Burnett RC, et al. Distinct B-cell and T-cell lymphoproliferative disease prevalence among dog breeds indicates heritable risk. Cancer Res. 2005;65(13):5654-5661.
Weiden PL, Storb R, Kolb HJ, et al. Immune reactivity in dogs with spontaneous malignancy. J Natl Cancer Inst. 1974;53(4):1049-1056.
Blackwood L, German AJ, Stell AJ, O’Neill T. Multicentric lymphoma in a dog after cyclosporine therapy. J Small Anim Pract. 2004;45(5):259-262.
Hoar SK, Blair A, Holmes FF, et al. Agricultural herbicide use and risk of lymphoma and soft tissue sarcoma. JAVMA. 1986;256(9):1141-1147.
Hayes HM, Tarone, RE, Cantor KP, Jessen CR, McCurnin DM, Richardson RC. Case-control study of canine malignant lymphoma: Positive association with dog owners’ use of 2, 4-dichlorphenoxyacetic acid herbicides. J Natl Cancer Inst. 1991;83(17):1226-1231.
Reif JS, Lower KS, Ogilvie GK. Residential exposure to magnetic fields and risk of canine lymphoma. Am J Epidemiol. 1995;141(4):352-359.
Madewell BR, Feldman BF. Characterization of anemias associated with neoplasia in small animals. JAVMA. 1980;176(5):419-425.
Weller RE. Paraneoplastic disorders in dogs with hematopoietic tumors. Vet Clin North Am Small Anim Pract. 1985;15(4):805-816.
Grindem CB, Breitschwerdt EB, Corbett WT, Page RL, Jans HE. Thrombocytopenia associated with neoplasia in dogs. JVIM. 1994;8(6):400-405.
Weir EC, Norrdin RW, Matus RE, et al. Humoral hypercalcemia of malignancy in canine lymphosarcoma. Endocrinology. 1988;122(2):602-608.
Valli VE, San Myint M, Barthel A, et al. Classification of canine malignant lymphomas according to the World Health Organization criteria. Vet Pathol. 2011;48(1):198-211.
Barber LG, Weishaar KM. Criteria for designation of clinical substage in canine lymphoma: A survey of veterinary oncologists. Vet Comp Oncol. 2014; doi:10.1111/vco.12086.
Jagielski D, Lechowski R, Hoffmann-Jagielska M, Winiarczyk S. Retrospective study of the incidence and prognostic factors of multicentric lymphoma in dogs (1998-2000). J Vet Med A Physiol Pathol Clin Med. 2002;49(8):419-424.
Keller ET, MacEwen EG, Rosenthal RC, Helfand SC, Fox LE. Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma. JVIM. 1993;7(5):289-295.
Sorenmo K, Overley B, Krick E, Ferrara T, LaBlanc A, Shofer F. Outcome and toxicity associated with a dose-intensified, maintenance-free CHOP-based chemotherapy protocol in canine lymphoma: 130 cases. Vet Comp Oncol. 2010;8(3):196-208.
Van Vleet JF, Ferrans VJ, Weirich WE. Cardiac disease induced by chronic adriamycin administration in dogs and an evaluation of vitamin E and selenium as cardioprotectants. Am J Pathol. 1980;99(1):13-42.
Mauldin GE, Fox PR, Patnaik AK, Bond BR, Mooney SC, Matus RE. Doxorubicin-induced cardiotoxicosis. Clinical features in 32 dogs. JVIM. 1992;6(2):82-88.
Thalheim L, Williams LE, Borst LB, Fogle JE, Suter SE. Lymphoma immunophenotype of dogs determined by immunohistochemistry, flow cytometry, and polymerase chain reaction for antigen receptor rearrangements. JVIM. 2013;27(6):1509-1516.
Poggi A, Miniscalco B, Morello E, et al. Prognostic significance of Ki67 evaluated by flow cytometry in dogs with high-grade B-cell lymphoma. Vet Comp Oncol. 2016;doi:10.1111/vco.12184.
Avery PR, Burton J, Bromberek JL, et al. Flow cytometric characterization and clinical outcome of CD4+ T-cell lymphoma in dogs: 67 cases. JVIM. 2014;28(2):538-546.
MacEwen EG, Brown NO, Patnaik AK, Passe S. Cyclic combination chemotherapy of canine lymphosarcoma. JAVMA. 1981;178(11):1178-1181.
Rosenthal RC, MacEwen EG. Treatment of lymphoma in dogs. JAVMA. 1990;196(5):774-781.
Garrett LD, Thamm DH, Chun R, Dudley R, Vail DM. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. JVIM. 2002;16(6):704-709.
Carter RF, Harris CK, Withrow SJ, Valli VEO, Susaneck SJ. Chemotherapy of canine lymphoma with histopathological correlation: doxorubicin alone compared to COP as first treatment regimen. JAAHA. 1987;23:587-596.
Postorino NC, Susaneck SJ, Withrow SJ, Harris C. Single agent therapy with Adriamycin for canine lymphosarcoma. JAAHA. 1988;25(2):221-225.
Sauerbrey ML, Mullins MN, Bannink EO, Van Dorp TE, Kaneene JB, Obradovich JE. Lomustine and prednisone as a first-line treatment for dogs with multicentric lymphoma: 17 cases (2004 -2005). JAVMA. 2007;230(12):1866-1869.
Risbon RE, de Lorimier LP, Skorupski K, et al. Response of canine cutaneous epitheliotropic lymphoma to lomustine (CCNU): A retrospective study of 46 cases (1999-2004). JVIM. 2006;20(6):1389-1397.
Palomba ML, Roberts WK, Dao T, et al. CD 8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma. Clin Canc Res. 2005;11(1):370-379.
Rodriguez C, Guerro T, Hansen G. Bioavailability and safety of caninized anti-CD52 monoclonal antibody in dogs with T-cell lymphoma. In: Proceedings of the 34th Annual Veterinary Cancer Society Conference. 2014; St. Louis, MO.
Bergman PJ, Liebman NF, Wolchok JD, et al. Phase 1 clinical trial of murine CD20 DNA vaccination in dogs with B-cell lymphoma. In: Proceedings of the 28th Annual Conference of the Veterinary Cancer Society. 2008; Seattle, WA;55.
Pawlak A, Rapak A, Drynda A, et al. Immunophenotypic characterization of canine malignant lymphoma: A retrospective study of cases diagnosed in Poland Lower Silesia, over the period 2011-2013. Vet Comp Oncol. 2014;doi:10.1111/vco.12112.
Thrall DE, Dewhirst MW. Use of radiation and/or hyperthermia for treatment of mast cell tumors and lymphosarcoma in dogs. Vet Clin North Am Small Anim Pract. 1985;15(4):835-843.
Meleo KA. The role of radiotherapy in the treatment of lymphoma and thymoma. Vet Clin North Am Small Anim Pract. 1997;27(1):115-129.
Williams LE, Johnson JL, Hauck ML, Ruslander DM, Price GS, Thrall DE. Chemotherapy followed by half-body radiation therapy for canine lymphoma. JVIM. 18(5):703-709.